Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering

By Agendia B.v., PRNE
Tuesday, March 23, 2010

New Service to Provide Breast Cancer Molecular Subtyping

HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 - Agendia, a world leader in molecular cancer diagnostics, today announced
that its breast cancer product offering, consisting of breast cancer
recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with
BluePrint (TM) to report important additional information on tumor subtypes.
This new service is based on an 80-gene signature that identifies the
basal-like, luminal-like, and HER2 molecular subtypes in breast cancer

"Using BluePrint, we will research potentially different responses of
therapies to biologically different subgroups together with our customers. In
the future, we envision the clinical utility of a combination of BluePrint
with MammaPrint's original 70-gene panel," said Richard Bender, MD, FACP,
Chief Medical Officer of Agendia. "We believe this combination has great
potential to bring the personalized treatment of breast cancer patients to a
new level."

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by
the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro
diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and
analytical validation and reporting systems to ensure patient safety issues
are addressed. Highly accurate, MammaPrint identifies patients with early
metastasis-patients who are likely to develop metastases within five years
following surgery. Several authoritative studies have shown that chemotherapy
particularly reduces early metastasis risk. In planning treatment, the
MammaPrint test results provide doctors with a clear rationale to assess the
benefit of chemotherapy in addition to other clinical information and
pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service
laboratory. Breast cancer recurrence assays currently marketed by other
manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting-edge genomics platform for tumor gene
expression profiling, the company's tests help physicians more accurately
tailor cancer treatments. Agendia markets four products, with several new
genomic tests under development. In addition, Agendia collaborates with
pharmaceutical companies to develop highly effective personalized drugs in
the area of oncology. The Company was awarded the 2008 North American
Oncology Clinical Diagnostics Healthcare Innovation Award by Frost &
Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam,
The Netherlands

MEDIA CONTACTS: Hans Herklots, Head of Corporate Communications, Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile, hans.herklots at; Valerie Delva, Account Executive, Ricochet Public Relations, +1-212-679-3300 x131 Office, vdelva at

will not be displayed